Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncor bladder cancer test trial to begin in late summer, JHU researcher says.

This article was originally published in The Gray Sheet

Executive Summary

ONCOR BLADDER CANCER DIAGNOSTIC CLINICAL TRIAL TO BEGIN AT JOHNS HOPKINS in the late summer to assess the utility of a new molecular diagnostic test, according to Johns Hopkins University investigator David Sidransky, who developed the test. Under the direction of JHU principal investigator Mark Schoenberg, the Phase II/III trial will enroll 300 patients and assess whether the test can diagnose bladder cancer earlier than the standard diagnostic procedures -- cytology, or testing cancer cells in the urine, and cystoscopy.

You may also be interested in...



Industry Ignored In Dispute Over UK Retailer’s ‘Weight Management’ Claim

Despite being defended by four industry representative bodies, UK health food retailer Holland & Barrett has been rapped for its use of “weight management” as a product category on its consumer-facing website by the country's Advertising Standards Authority. 

WHO To Clean Up Data Integrity Failings

The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date. 

Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

UsernamePublicRestriction

Register

MT004315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel